Skip to content

Constipation and Gut Transit in DMD Patients

Constipation and Gut Transit in Duchenne Muscular Dystrophy Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01890616
Enrollment
8
Registered
2013-07-02
Start date
2013-05-01
Completion date
2015-07-01
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation, DMD

Brief summary

In this research study the investigators want to screen Duchenne Muscular Dystrophy (DMD) patients for signs and symptoms of constipation in patients over 18. The investigators hypothesized: * DMD patients have a high prevalence of constipation than in the general population. * Prevalence of constipation will increase with age and with worsening functional status.

Detailed description

The following procedures will take place during the study. Constipation Assessment: * The patient will be asked to complete a questionnaire about any symptoms of constipation. * A physician from the study team will perform an abdominal physical exam * The patient will have routine x-rays that monitor for spine compression fractures. These films will also be used to assess stool content. Clinical Information The following information will also be collected during the clinic visit ; * Age at diagnosis and genetic mutation * Age at loss of ambulation if applicable * Medications * Functional status

Interventions

DEVICESmartPill ingestion

The participant would ingest the SmartPill and wear the data receiver for up to 5 days.

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a diagnosis of Duchenne Muscular Dystrophy (based on clinical presentation and verified by compatible muscle biopsy or known dystrophin gene mutation). * Age greater than or equal to 18 years old

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
GI transit timesup to 5 daysGi transit times will be computed by an investigator.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026